免疫调节药物：急性髓系白血病（AML）的小分子免疫调节药物

Title:Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML)

Volume: 18 Issue: 3

Author(s): Joshua F. Zeidner, Matthew C. Foster.

Affiliation:

关键词: 急性髓系白血病，免疫治疗，小分子免疫调节药物，来那度胺，pomalidomide，沙利度胺。

摘要: AML patients have an aberrant and dysfunctional immune state, paving the way for novel agents targeting pathways that integrate with immune signaling, function, and response. Small molecule immunomodulatory drugs (IMiDs) represent a class of agents derived from the parent compound, thalidomide. There are currently 3 IMiDs approved for a variety of malignancies: thalidomide, lenalidomide, and the newest agent, pomalidomide. IMiDs lead to a multitude of immunobiologic effects such as cytokine modulation, co-stimulation of T cells, down-regulation of co-inhibitory molecules, enhancing natural killer cell activity, inhibition of regulatory T cells, and repairing perturbed synapse formation on T cells. IMiDs have been extensively studied in various AML settings with promising clinical activity. This review discusses the immunologic effects of IMiDs, the rationale for studying IMiDs in AML, and the published and ongoing clinical trials investigating IMiD activity in AML.

Cite this article as:

Joshua F. Zeidner, Matthew C. Foster. , Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML), Current Drug Targets 2017; 18 (3) . https://dx.doi.org/10.2174/1389450116666150304104315